COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #24 of 237
5/2 Late treatment study
Mallat et al., Medicine (Baltimore), doi:10.1097/MD.0000000000023720 (preprint 5/2) (Peer Reviewed)
Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study
Source   PDF   Share   Tweet
Very small retrospective analysis of 34 patients finding slower binary PCR viral clearance with HCQ. No information on severity for treatment versus control is provided. No deaths, ICU admission, or mechanical ventilation. Binary PCR does not distinguish replication-competence. HCQ treatment started very late for many patients with >= 9 days for 25%.

Mallat et al., 5/2/2020, retrospective, Abu Dhabi, Middle East, peer-reviewed, 8 authors.
time to viral-, 203.0% higher, relative time 3.03, p = 0.02, treatment 23, control 11.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit